California Institute for Regenerative Medicine expands therapy access in Northern…
What happened
The California Institute for Regenerative Medicine approved $9 million for Enloe Health in Chico, California, to establish a Community Care Center of Excellence. This center will connect residents in Northern California with FDA-approved cell and gene therapies and clinical trials. The center will initially focus on delivering approved CAR-T therapies and trials for conditions like blood cancers and autoimmune diseases.
From manilatimes.net
Why it matters
The expansion is part of a program launched by the California Institute for Regenerative Medicine to improve access to regenerative medicine therapies for Californians living far from major medical centers. The center will provide clinical trial opportunities, patient support, and workforce training.
From manilatimes.net
Who's involved
- California Institute for Regenerative MedicineApproved $9 million to establish the Community Care Center of Excellence.
- FDAApproves the cell and gene therapies that the new center will deliver.
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
The California Institute for Regenerative Medicine might see increased funding and revenue from the successful expansion of its clinical network.
- CRISPR TherapeuticsSpeculative
CRISPR Therapeutics could see increased investment and sales validation due to the expanded market demand for advanced cell and gene therapies.
Keep exploring
The entities involved
-
Northern California
region of California, United States
-
California Institute for Regenerative Medicine
research institute in California, United States
Nothing else this week.
- FDA
Related events
- Fate Therapeutics, based in San Diego, is seeking support for an accelerated regulatory pathway from the FDA.
- FDA is willing to review updated submissions, while biotech hubs leverage AI to ease clinical development bottlenecks.
- FDA placed a clinical hold on a gene therapy involving Hunter.
- Solid Biosciences received FDA approval for a gene therapy trial on July 9, 2025.
- The FDA reviewed gene therapy applications and provided milestone payments for dosing involving Regenxbio and AbbVie.